Briacell Therap (NASDAQ:BCTX) Short Interest Update

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant growth in short interest in March. As of March 13th, there was short interest totaling 145,756 shares, a growth of 40.2% from the February 26th total of 103,944 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average daily volume of 273,289 shares, the short-interest ratio is currently 0.5 days.

Briacell Therap Stock Down 3.6%

Briacell Therap stock opened at $3.75 on Friday. The firm has a market capitalization of $27.19 million, a PE ratio of -0.16 and a beta of 1.46. Briacell Therap has a 52 week low of $3.60 and a 52 week high of $98.20. The firm’s 50-day simple moving average is $4.17 and its 200 day simple moving average is $7.87.

Briacell Therap (NASDAQ:BCTX) last announced its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter. On average, research analysts expect that Briacell Therap will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new stake in shares of Briacell Therap (NASDAQ:BCTX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap as of its most recent SEC filing. 15.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $320.00.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.